ESPR - Esperion Therapeutics, Inc.
收市後：
| 前收市價 | 1.3500 |
| 開市 | 1.3500 |
| 買盤 | 0.0000 x 3100 |
| 賣出價 | 0.0000 x 1000 |
| 今日波幅 | 1.3250 - 1.4450 |
| 52 週波幅 | 1.1200 - 8.8700 |
| 成交量 | |
| 平均成交量 | 3,778,365 |
| 市值 | 129.756M |
| Beta 值 (5 年，每月) | 0.12 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.2800 |
| 業績公佈日 | 2023年7月31日 - 2023年8月04日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 10.19 |
InvestorPlace7 Very Undervalued Penny Stocks to Buy in April 2023
Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price. It is also worth noting that penny stocks are highly risky and it goes without saying that losses aren’t uncommon. In other words, don’t treat these stocks the same as their more stable counterparts, and only invest what you can afford to lose. That said, the penny stocks listed here are interesting and fall, for the most
BenzingaEsperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors
Esperion Therapeutics Inc (NASDAQ: ESPR) announced the full results from the CLEAR Outcomes trial, a global study of nearly 14,000 patients with or at risk for cardiovascular disease who were unable to maximize or tolerate a statin. The study showed that Nexletol (Bempedoic acid) significantly reduced the risk of hard MACE-4 and MACE-3 by 13% and 15%, respectively, and significantly reduced the risk of heart attack and coronary revascularization by 23% and 19%, respectively, compared to placebo.
BenzingaEsperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
Esperion Therapeutics Inc's (NASDAQ: ESPR) CLEAR Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL (bempedoic acid) compared to placebo. The data demonstrate statistically significant and clinically meaningful results. The study included over 14,000 patients at over 1,200 sites in 32 countries. Bempedoic acid becomes the first ATP citrate lyase inhibitor and oral non-statin to meet the major adve